ALX Oncology Holdings Inc.
ALXO
$0.55
-$0.01-1.79%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 35.87% | 39.78% | -15.34% | -17.88% | -48.07% |
| Total Depreciation and Amortization | 3.38% | -1,380.00% | 54.52% | 0.47% | 97.14% |
| Total Amortization of Deferred Charges | 7.81% | 4.76% | 6.45% | 4.92% | 45.45% |
| Total Other Non-Cash Items | 7.74% | 20.41% | 26.17% | 7.13% | -12.28% |
| Change in Net Operating Assets | -2,746.53% | -109.36% | 328.81% | -148.20% | -91.67% |
| Cash from Operations | 19.23% | 18.56% | 16.22% | -36.34% | -91.98% |
| Capital Expenditure | 59.46% | -111.44% | 94.82% | 78.55% | 61.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 301.25% | 124.48% | -87.46% | -38.07% | -245.78% |
| Cash from Investing | 299.11% | 100.49% | -85.40% | -37.41% | -252.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -20.63% | -222.52% | -103.74% | -63.55% | 41.12% |
| Issuance of Common Stock | -99.93% | -- | 6,854.22% | -- | 24,755.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 108.16% | -- | -- | -- | -571.76% |
| Cash from Financing | -99.45% | 326.13% | 7,816.03% | 2,984.11% | 523.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -48.09% | 103.08% | 105.94% | -158.20% | 1,316.38% |